Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Takeda Pharmaceutical ADR Rep 0.5 Ord Shs V.TAK


Primary Symbol: TAK

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.


NYSE:TAK - Post by User

Post by rory17on Dec 14, 2012 3:53pm
200 Views
Post# 20732718

yukoninvestor

yukoninvestor

You are right. The unfortunate part about TAK is that management has stumbled along when it came to drilling and where to drill. Poor planning and execution. The management has paid themselves a lot of money over the last few years especially Dingsdale and Fekete. They and some members of their board were also promoting other deals as well while trying to run TAK at the same time.  Between July 2010 and November  2010 retail and institutional investors put $10,450,000 in the company coffers. Their overall execution speaks for itself and in 6 months they say they will be out of money. My advice to them is to stop paying themselves  fees or salaries to preserve funds and make some big changes in management. The chances of these guys raising any funds is next to zero. The New Year could get interesting for this management team IMO

Bullboard Posts